Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RYZ401 in Neuroendocrine Tumors and Other Solid Tumors
NCT07165132Phase 1Recruiting
- Sponsor
- RayzeBio
- Start
- Dec 2025
- Primary completion
- Feb 2027
- Modality
- Radiopharmaceutical
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of RYZ401 in Neuroendocrine Neoplasm (NEN), meningioma and solid tumor, sponsored by RayzeBio. Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Dose Expansion Outcomes. Started Dec 2025; status: recruiting.
02
Drugs
RYZ401
03
Conditions
Neuroendocrine Neoplasm (NEN)meningiomasolid tumor
Beyond the preview
Go deeper on NCT07165132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165132.